Taiki Hayasaka MD, PhD , Bruno Moukette PhD , Marisa N. Sepúlveda PhD , Satoshi Kawaguchi MD, PhD , Tatsuya Aonuma MD, PhD , Hamedane Moustapha MS , Lei Yang PhD , Meena S. Madhur MD, PhD , Suthat Liangpunsakul MD , Il-man Kim PhD
{"title":"Periostin is a Pivotal Target of microRNA-150-5p in Cardiac Fibroblast Activation and Chronic Myocardial Infarction","authors":"Taiki Hayasaka MD, PhD , Bruno Moukette PhD , Marisa N. Sepúlveda PhD , Satoshi Kawaguchi MD, PhD , Tatsuya Aonuma MD, PhD , Hamedane Moustapha MS , Lei Yang PhD , Meena S. Madhur MD, PhD , Suthat Liangpunsakul MD , Il-man Kim PhD","doi":"10.1016/j.jacbts.2025.101330","DOIUrl":null,"url":null,"abstract":"<div><div>Our prior studies have revealed that miR-150-5p (miR-150) attenuated cardiac dysfunction in mice, which overexpressed a long noncoding RNA called myocardial infarction–associated transcript during myocardial infarction or harbored cardiac-specific abrogation of β-arrestin–mediated β<sub>1</sub>-adrenergic receptor signaling during chronic catecholamine stimulation. Although previous studies have shown the importance of miR-150 in heart failure, details surrounding its actions remain elusive in part because of (1) the lack of detailed mechanistic insight by which this small noncoding RNA induces myocardial protection and (2) the absence of definitive studies using appropriate mouse models to establish its direct functional relationship with key downstream targets. In the current study, we provide strong evidence that fibrotic periostin is a significant downstream target of miR-150 repression in ischemic mouse hearts. To the best of our knowledge, this is the first study to directly establish the functional link between miR-150 and periostin in murine myocardial infarction and primary adult human cardiac fibroblast activation.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 8","pages":"Article 101330"},"PeriodicalIF":8.4000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25002827","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Our prior studies have revealed that miR-150-5p (miR-150) attenuated cardiac dysfunction in mice, which overexpressed a long noncoding RNA called myocardial infarction–associated transcript during myocardial infarction or harbored cardiac-specific abrogation of β-arrestin–mediated β1-adrenergic receptor signaling during chronic catecholamine stimulation. Although previous studies have shown the importance of miR-150 in heart failure, details surrounding its actions remain elusive in part because of (1) the lack of detailed mechanistic insight by which this small noncoding RNA induces myocardial protection and (2) the absence of definitive studies using appropriate mouse models to establish its direct functional relationship with key downstream targets. In the current study, we provide strong evidence that fibrotic periostin is a significant downstream target of miR-150 repression in ischemic mouse hearts. To the best of our knowledge, this is the first study to directly establish the functional link between miR-150 and periostin in murine myocardial infarction and primary adult human cardiac fibroblast activation.
期刊介绍:
JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.